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Alteration of aberrant DNA methylation is one of the most consistent epigenetic changes 
found in human cancers.  DNA methylation is catalyzed by DNA methyltransferase 
(DNMT).  In this study, we examined DNMT protein expression by immunohistochemis-
try in surgically resected hepatocellular carcinomas (HCCs).  Sections of paraffin-embed-
ded specimens were obtained from 95 patients with HCC between 1989 and 2002.  The 
specimens were stained with anti-DNMTs (DNMT1, DNMT3a and DNMT3b) antibodies. 
There were statistically significant associations between DNMT protein expression and 
tumor differentiation (P < 0.05) and intrahepatic metastasis (P < 0.05).  DNMT3a protein 
expression was significantly correlated with portal vein involvement of tumors (P < 0.05). 
The overall survival rates of patients with DNMT3a-positive HCCs and DNMT3b-positive 
HCCs were significantly lower than those of patients negative for these proteins (P < 0.005, 
respectively).  To further evaluate the correlation between DNMT protein expression and 
patient survival, we classified patients into 3 groups: Group 1, DNMT1(+), 3a(–) and 3b(–); 
Group 2) DNMT1(+), 3a or 3b(+); and Group 3) DNMT1(+), 3a(+) and 3b(+).  The over-
all survival rate of patients in Group 3 was significantly lower than those of patients in 
Groups 1 and 2 (P = 0.0009).  In conclusion, the results of this study suggest that DNMT1, 
DNMT3a and DNMT3b are cooperatively involved in determining the extent of HCCs, 
and that DNMT protein overexpression in HCCs may be a predictive factor for poor sur-
vival.  
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DNA methylation plays an important role in the 
regulation of gene expression, and gene silencing 
by aberrant hypermethylation of CpG islands in 
gene promoter regions frequently occurs in human 
cancers.  DNA methyltransferases are involved 
in the transfer of methyl groups to promoter CpG 
islands, and many tumor suppressor genes can 
be silenced by promoter CpG island methylation. 
Alteration of aberrant DNA methylation is one of 
the most consistent epigenetic changes found in hu-
man cancers (Girault et al., 2003; Ding et al., 2008; 
Nosho et al., 2009).
 DNA methyltransferases have been reported 
to be encoded by 3 distinct families of DNMT 
genes: DNMT1, DNMT2, and DNMT3.  DNMT1 
is the best known DNMT involved in the mainte-
nance of methylation, while DNMT3 is involved 
in de novo methylation and is encoded by 2 dis-
tinct genes, DNMT3a and DNMT3b (Łuczak and 
Jagodzinski, 2006).  The function of DNMT2 
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remains to be determined.  Interactions among 
DNMTs and methyl CpG-binding domain proteins 
should also be considered as a mechanism for 
maintaining DNA methylation patterns using the 
proofreading or remethylation function (Hattori et 
al., 2004).
 Aberrant hypermethylation of CpG islands 
has recently been implicated in hepatocarcinogen-
esis, and it has been reported that tumor suppressor 
genes in hepatocellular carcinomas (HCCs) are 
affected by such silencing (Saito et al., 2001; Yang 
et al., 2003).  To study the significance of aberrant 
DNMT (DNMT1, 3a and 3b) expression in human 
HCC, we evaluated the correlation between DNMT 
protein expression and clinicopathologic features 
and prognosis in patients with HCC.
 
Materials and Methods
Patients and samples 
 
Stored HCC and corresponding non-cancerous tis-
sue specimens from our laboratory were obtained 
for 95 patients from 1989 to 2002.  The proto-
col was approved by the ethics committee of the 
School of Medicine, Tottori University (1040).  In-
formed consent was obtained from all patients. 
 The clinicopathologic features of the 95 pa-
tients are shown in Table 1.  A mean age was 61 
± 10 years (range, 17–80 years).  For comparison, 
normal liver tissues were also obtained from 3 
patients who had undergone surgical resection for 
hepaticolithiasis.
Table 1.  Relationship between DNMTs and tissue specimens
   Patients n Immunostaining score
  DNMT1 DNMT3a DNMT3b
Age (year)       
     < 60 39 2.179 ± 0.721 NS 1.897 ± 0.882 NS 1.205 ± 0.656 NS
     ≥ 60 56 2.357 ± 0.586  1.786 ± 0.847  1.232 ± 0.831 
Sex       
     Male 76 2.263 ± 0.640 NS 1.776 ± 0.873 NS 1.145 ± 0.905 NS
     Female 19 2.368 ± 0.684  2.053 ± 0.800  1.526 ± 0.905 
Background of cancerous liver tissue       
     Chronic hepatitis 27 2.370 ± 0.655 NS 1.556 ± 1.013 NS 1.000 ± 0.679 NS
     Liver cirrhosis 68 2.250 ± 0.629  1.941 ± 0.770  1.309 ± 0.778 
Tumor differentiation       
     Well differentiated 19 1.842 ± 0.765 P < 0.05 1.421 ± 0.769 P < 0.05 0.895 ± 0.657 P < 0.05
     Moderately differentiated 59 2.339 ± 0.633  1.814 ± 0.880  1.254 ± 0.779 
     Poorly differentiated 17 2.471 ± 0.624  2.235 ± 0.831  1.412 ± 0.870 
Portal vein involvement of tumor       
     Positive 51 2.314 ± 0.678 NS 2.000 ± 0.849 P < 0.05 1.294 ± 0.782 NS
     Negative 44 2.250 ± 0.615  1.636 ± 0.838  1.136 ± 0.734 
Pathological findings Fc-inf       
     Positive 68 2.319 ± 0.675 NS 1.870 ± 0.873 NS 1.188 ± 0.791 NS
     Negative 27 2.192 ± 0.567  1.731 ± 0.827  1.308 ± 0.679 
Intrahepatic metastasis       
     Positive 28 2.571 ± 0.504 P < 0.05 2.143 ± 0.803 P < 0.05 1.464 ± 0.693 P < 0.05
     Negative 67 2.164 ± 0.665  1.701 ± 0.853  1.119 ± 0.769 
Tumor size       
     ≤ 20 mm 22 2.136 ± 0.640 NS 1.864 ± 0.774 NS 1.273 ± 0.767 NS
     > 20 mm or < 50 mm 50 2.400 ± 0.670  1.800 ± 0.948  1.180 ± 0.800 
     ≥ 50 mm 23 2.087 ± 0.733  1.783 ± 0.723  1.217 ± 0.736 
n, number of patients.
Fc-inf, infiltration to the capsule; NS, not significant.
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Immunohistochemistry
 
Formalin-fixed, paraffin-embedded tissues were cut 
into 4-μm-thick continuous sections and mounted 
on poly-L-lysine-coated glass slides.  Slides were 
deparaffinized in xylene, rehydrated in graded al-
cohols and washed in tap water.  Endogenous per-
oxidase activity was blocked by incubating sections 
in 3% H2O2.  Slides were heated in a microwave at 
600 W for 15 min with 10 mM sodium citrate buf-
fer (pH 6.0) and treated with polyoxyethylene sorbi-
tan monolaurate (Tween 20) for 30 min for antigen 
retrieval.  Rabbit polyclonal antibodies for DNMT1 
(H-300, sc-20701, dilution 1:200), DNMT3a (H-295, 
sc-20703, dilution 1:200) and DNMT3b (H-230, 
sc-20704, dilution 1:200) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) were applied overnight, fol-
lowed by incubation with biotinylated secondary 
antibodies [anti-rabbit IgG, N-Histofine, Simple 
Stain MAX PO (MULTI)] at room temperature for 
30 min.  Antigen-antibody complexes were visual-
ized using a streptavidin-horseradish peroxidase 
conjugate (LSAB kit; Dako, Carpinteria, CA) with 
diaminobenzidine as a chromogen.  Slides were 
counterstained with Harris’ hematoxylin and meth-
ylgreen for 3 to 5 s.
 
Scoring of immunoreactivity
 
Two independent observers (T.M. and K.E.) inde-
pendently evaluated the immunostaining without 
knowledge of the clinical outcomes; the concor-
dance ratio was > 90%.  When differences in scor-
ing were encountered, a consensus of two was used 
to obtain a final decision.
 Nuclear positivities for the 3 proteins were 
evaluated using the scoring system previously re-
ported by Choi et al. (2003), according to staining 
intensity (0, negative; 1, weak; 2, moderate; and 3, 
severe) and proportion of positive cells (0, negative; 
1, positive in ≤ 10%; 2, positive in > 10% and ≤ 
33%; 3, positive in > 33% and ≤ 66%; 4, positive in 
> 66% of cells).  The 2 scores were added in each 
case, and the expression was graded as – (0), 1+ (1 
or 2), 2+ (3 to 5) and 3+ (6 or 7).
Table 2.  Expression of DNMT 1, 3a and 3b pro-
teins in patients with hepatocellular carcinoma
 DNMT protein expression
 –  1+ 2+ 3+
 n (%) n (%) n (%) n (%)
DNMT1 0  (0) 10  (10.5) 50  (52.6) 35  (36.8)
DNMT3a 8  (8.4) 20  (21.1) 48  (50.5) 19  (20.0)
DNMT3b 14  (14.7) 51  (53.7) 25  (26.3) 5  (5.2)
n, number of patients:  total number, 95.
Nuclear positivities for the 3 proteins were evaluated using 
the scoring system, according to staining intensity (0, nega-
tive; 1, weak; 2, moderate; and 3, severe) and proportion of 
positive cells (0, negative; 1, positive in ≤ 10%; 2, positive in 
> 10% and ≤ 33%; 3, positive in > 33% and ≤ 66%; 4, posi-
tive in > 66% of cells).  The 2 scores are added in each case, 
and the expression is graded as – (0), 1+ (1 or 2), 2+ (3 to 5) 
and 3+ (6 or 7).
 
Statistical analysis
 
Statistical analysis was performed using Prism soft-
ware (GraphPad Software, La Jolla, CA).  Spear-
man’s rank correlation test and Student’s t-test were 
used to study the relationships between DNMT im-
munoreactivities and various clinicopathologic pa-
rameters.  Overall survival rates were determined 
by the Kaplan-Meier method, and the significance 
of differences between survival rates was studied 
using the log-rank test.  Differences or correlations 
with P values < 0.05 were considered significant. 
Positive DNMT expression was defined as moder-
ate (2+) or strong (3+), and negative DNMT expres-
sion as absent (–) or weak (1+) expression.  To fur-
ther evaluate the correlation between DNMT pro-
tein expression and patient survival, we subdivided 
the patients into 3 groups: Group 1) DNMT1(+), 
3a(–) and 3b(–); Group 2) DNMT1(+), 3a or 3b(+); 
and Group 3) DNMT1(+), 3a(+) and3b (+).
 
 
Results
 
The immunohistochemical staining results are 
shown in Table 2 and Fig. 1.  The non-cancerous 
liver tissues showed no expression of nuclear 
DNMT proteins by immunohistochemistry.  There 
were no differences in cytoplasmic DNMT expres-
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Fig. 1.  Immunohistochemical staining results for (a) DNMT1, 
(b) DNMT3a and (c) DNMT3b proteins in hepatocellular 
carcinomas.  Strong nuclear expression and faint cytoplasmic 
expression are seen in these 3 cases.  a and b: counterstained 
with Harris’ hematoxylin.  c: conterstained with methylgreen. 
Bar = 100 µm.
Fig. 2.  Kaplan-Meier survival curves for patients 
with hepatocellular carcinomas according to DNMT 
protein expression levels.  [   ], number of patients. 
  a:  DNMT 1.
 b:  DNMT 3a. 
 c:  DNMT 3b.
a
b
c
sion between patients with CH and LC (data not 
shown).  None of the 3 normal control livers dem-
onstrated nuclear expression of DNMTs.
 We indicated the immunostaining scores 
according to the clinicopathological findings in 
Table 1.  There were significant associations be-
tween DNMT protein expression and tumor dif-
ferentiation or intrahepatic metastasis.  DNMT3a 
protein expression was significantly correlated with 
portal vein involvement in the tumor.  On the other 
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hand, no significant correlations were noted be-
tween DNMT1 or 3b and portal vein involvement. 
There were no significant associations between 
DNMT expression and age, sex, tumor size, infil-
tration to the capsule or underlying liver disease.  
 Follow-up information was available for all 
95 patients, covering periods ranging from 0 to 183 
months (mean, 63.7 months).  Kaplan-Meier surviv-
al curves were plotted for the 95 patients according 
to expression of each DNMT.
 The overall survival rates of DNMT3a-
positive and DNMT3b-positive HCC patients were 
significantly lower than those of patients negative 
for these proteins (Fig. 2b, P = 0.003, log-rank 
test; Fig. 2c, P = 0.0034, log-rank test).  However, 
the overall survival rate of DNMT1-positive HCC 
patients was not significantly different from that of 
DNMT1-negative HCC cases (Fig. 2a, P = 0.1038, 
log-rank test).
 The overall survival rate of patients in Group 
3 [DNMT1(+), 3a(+) and 3b(+)] was significantly 
lower than those of patients in Groups 1 and 2 
(Fig. 3, P = 0.0009, log-rank test). 
 
 
Discussion
 
DNA methylation is well known to be involved 
in the early developmental stages of HCC with a 
background of chronic liver disease, including CH 
and LC.  It has recently been suggested that aber-
rant DNA methylation of CpG islands is an early 
Fig. 3.  Kaplan-Meier survival curves 
were plotted for 94 patients accord-
ing to the correlation with expression 
of the DNMT protein complex.  [   ], 
number of patients.
Group 1:  DNMT1(+), 3a(–) and 3b(–).
Group 2:  DNMT1(+), 3a or 3b(+).
Group 3:  DNMT1(+), 3a(+) and 3b(+).
and frequent event, and that stepwise progression 
of methylating events contributes to multistep hepa-
tocarcinogenesis (Roncalli et al., 2002; Lee et al., 
2003; Yang et al., 2003).  The levels of DNMT1, 
DNMT3a and DNMT3b mRNA in HCCs are sig-
nificantly higher than in noncancerous liver tissues, 
including normal, chronic CH and LC tissues (Saito 
et al., 2001; Oh et al., 2007).  
 In the present study, we used an immunohis-
tochemical technique to directly examine the pro-
tein expression of 3 DNMTs in HCCs.  The results 
demonstrated that DNMT protein expression in 
HCCs was significantly higher than in noncancer-
ous liver tissues including normal, CH and LC tis-
sues.  In addition, there was no significant relation-
ship between DNMT expression, CH and LC.
 Immunohistochemical staining showed very 
strong nuclear expression and faint cytoplasmic 
expression of DNMT1, and strong nuclear and faint 
cytoplasmic expression of DNMT3a and DNMT3b. 
Some immunohistochemical staining of these 
DNMTs has previously been performed in a vari-
ety of cancers (Girault et al., 2003; Lin et al., 2007; 
Ding et al., 2008) and HCC (Saito et al., 2003; Oh 
et al., 2007).  Although nuclear and cytoplasmic 
DNMT3b expression has been detected in other 
cancers, no results of immunohistochemical stain-
ing of DNMT3b have previously been reported in 
HCC.
 The present study showed a significant re-
lationship between DNMT3a protein expression 
and portal vein involvement, and significant rela-
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tionships between DNMT protein expression and 
tumor differentiation or intrahepatic metastasis. 
However, a previous report found no significant 
relationship between DNMT mRNA levels and 
portal vein involvement and tumor differentiation 
in HCCs (Saito et al., 2001), but the same research 
group reported a significant relationship between 
DNMT1 protein expression and portal vein in-
volvement or tumor differentiation (Saito et al., 
2003).  Reverse transcriptase-polymerase chain 
reaction is sufficiently sensitive to detect small el-
evations in DNMT mRNA levels, while immuno-
histochemistry is only able to detect elevations in 
protein expression when they reach a certain level 
in more malignant HCCs.  We suggest that DNMT 
protein expression may be more strongly correlated 
with progression of the cancerous stage of HCCs, 
rather than the precancerous stage.  To the best of 
our knowledge, there have been no reports of any 
significant relationship between DNMT protein 
expression and intrahepatic metastasis, and there 
have been some reports of a lack of any significant 
relationship between DNMT protein expression 
and lymphogenous metastasis in other cancers 
(Ding et al., 2008; Nosho et al., 2009).  However, 
the relationship between DNMT protein expres-
sion and hematogenous metastasis has not been 
previously reported.  E-cadherin, an intercellular 
adhesion-related protein, is coded for by a tumor 
suppressor gene.  E-cadherin gene methylation has 
been associated with reduced expression of the pro-
tein, resulting in a loss of intercellular adhesion and 
tissue destruction in HCCs (Kanai et al., 1997).  In 
a recent study, E-cadherin expression was reported 
to be significantly increased after concomitant 
siRNA-mediated depletion of DNMT1, 3a and 3b 
in endometrial epithelial carcinoma cells (Rahnama 
et al., 2009).  DNMTs are thought to be involved in 
E-cadherin methylation.  In addition, reduction of 
E-cadherin may also be related to the acquisition of 
cell motility, tumor cell invasion and vascular inva-
sion.  E-cadherin gene methylation in HCCs has 
been shown to be associated with a poor prognosis 
(Kozyraki et al., 1996; Lee et al., 2003).  DNMT 
protein expression may therefore contribute to he-
matogenous metastasis in HCC.
 We investigated the relationship between 
expression of the 3 DNMTs and overall patient 
survival.  This is the 1st report to reveal poor over-
all survival in HCC patients with positive immu-
noreactivity for DNMT3a and DNMT3b protein 
expression.  No significant relationship between 
DNMT1 protein expression and overall patient sur-
vival was noted, though some studies on HCC and 
lung cancers have shown a significant relationship 
between DNMT1 protein expression and overall 
survival (Saito et al., 2003; Lin et al., 2007).  The 
reasons for this discrepancy remain to be deter-
mined.  DNMT1 is referred to as a “maintenance” 
methyltransferase, and DNMT1 protein expression 
may thus not contribute to overall survival.  How-
ever, our study demonstrated a significant relation-
ship between protein expression of the 3 DNMTs 
and poor overall survival in HCCs.  It was recently 
reported that DNMT1 and DNMT3a/3b may as-
sociate directly and function as a complex for DNA 
methylation of CpG islands (Kim et al., 2002; Rhee 
et al., 2002; Hattori et al., 2004).  The results of the 
present study suggest that DNMT1, DNMT3a and 
DNMT3b may be cooperatively involved in de-
termining the extent of HCCs.  Thus each DNMT 
could affect survival in patients with HCC.
 DNA methylation is known to be a reversible 
process.  In a previous study, promoter methylation 
by DNMT was shown to be reversible using the 
DNMT inhibitor 5-aza-2’-deoxycytidine, which in-
duced re-expression of promoter-methylated genes 
in a cell line in vitro (Juttermann et al., 1994; Yang 
et al., 2001; Arai et al., 2006).  5-Aza-2’-deoxycy-
tidine and 5-azacytidine in non-toxic doses have 
been approved by the United States Food and Drug 
Administration as DNMT inhibitors for hemato-
logical malignancies (Mulero-Navarro and Esteller, 
2008).  The relationship between DNMT protein 
expression and patient prognosis demonstrated in 
the present study suggests a potentially important 
role for DNMT inhibitor therapy in HCC patients 
with an increased DNMT protein expression.
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 In conclusion, the present study suggests that 
overexpression of DNMT proteins in HCCs may be 
a predictive factor for poor survival.  In addition, 
DNMTs may represent new prognostic markers 
and potential therapeutic targets in HCC.
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